These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 33105647)

  • 1. Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update.
    Utsunomiya A; Oyama N; Hasegawa M
    J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33105647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers in systemic sclerosis: Their potential to predict clinical courses.
    Hasegawa M
    J Dermatol; 2016 Jan; 43(1):29-38. PubMed ID: 26782004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BIOMARKERS OF DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS.
    Pawlik KK; Bohdziewicz A; Chrabąszcz M; Stochmal A; Sikora M; Alda-Malicka R; Czuwara J; Rudnicka L
    Wiad Lek; 2020; 73(10):2300-2305. PubMed ID: 33310967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of skin and lung fibrosis in systemic sclerosis.
    Martinović Kaliterna D; Petrić M
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1215-1223. PubMed ID: 31539483
    [No Abstract]   [Full Text] [Related]  

  • 6. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on biomarker discovery and use in systemic sclerosis.
    Matsushita T; Takehara K
    Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
    Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
    Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
    Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis.
    Cavagna L; Caporali R; Klersy C; Ghio S; Albertini R; Scelsi L; Moratti R; Bonino C; Montecucco C
    J Rheumatol; 2010 Oct; 37(10):2064-70. PubMed ID: 20634241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
    Hant FN; Ludwicka-Bradley A; Wang HJ; Li N; Elashoff R; Tashkin DP; Silver RM;
    J Rheumatol; 2009 Apr; 36(4):773-80. PubMed ID: 19286849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
    Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
    Shirai Y; Fukue R; Kaneko Y; Kuwana M
    Diagnostics (Basel); 2021 Oct; 11(11):. PubMed ID: 34829353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis.
    Fukayama M; Yoshizaki A; Fukasawa T; Ebata S; Kuzumi A; Yoshizaki-Ogawa A; Asano Y; Oba K; Sato S
    J Dermatol; 2020 Nov; 47(11):1287-1292. PubMed ID: 32686186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating biomarkers of systemic sclerosis - interstitial lung disease.
    Hoffmann-Vold AM; Fretheim H; Meier C; Maurer B
    J Scleroderma Relat Disord; 2020 Mar; 5(2 Suppl):41-47. PubMed ID: 35382223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.
    Choi HJ; Shin YK; Lee HJ; Kee JY; Shin DW; Lee EY; Lee YJ; Lee EB; Song YW
    Clin Rheumatol; 2008 Apr; 27(4):437-42. PubMed ID: 17899307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulatory Serum Krebs von Den Lungen-6 and Surfactant Protein-D Concentrations Predict Interstitial Lung Disease Progression and Mortality.
    Rai M; Parthasarathi A; Beeraka NM; Kaleem Ullah M; Malamardi S; Padukudru S; Siddaiah JB; Uthaiah CA; Vishwanath P; Chaya SK; Ramaswamy S; Upadhyay S; Ganguly K; Mahesh PA
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers in connective tissue disease-associated interstitial lung disease.
    Bonella F; Costabel U
    Semin Respir Crit Care Med; 2014 Apr; 35(2):181-200. PubMed ID: 24668534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.
    Khanna D; Tashkin DP; Denton CP; Renzoni EA; Desai SR; Varga J
    Am J Respir Crit Care Med; 2020 Mar; 201(6):650-660. PubMed ID: 31841044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of cardiac natriuretic peptide on pulmonary hypertension in systemic sclerosis: A systematic review and meta-analysis.
    Zhang Y; Qin D; Qin L; Yang X; Luo Q; Wang H
    Joint Bone Spine; 2022 Mar; 89(2):105287. PubMed ID: 34601113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.